ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections

ClinicalTrials.gov ID: NCT02784704

Public ClinicalTrials.gov record NCT02784704. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 3:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections

Study identification

NCT ID
NCT02784704
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Enrollment
500 participants

Conditions and interventions

Interventions

  • Eravacycline Drug
  • Meropenem Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 12, 2016
Primary completion
May 7, 2017
Completion
May 18, 2017
Last update posted
Jan 5, 2022

2016 – 2017

United States locations

U.S. sites
6
U.S. states
5
U.S. cities
6
Facility City State ZIP Site status
Not listed Los Angeles California
Not listed Indianapolis Indiana
Not listed Las Vegas Nevada
Not listed Somers Point New Jersey
Not listed Cleveland Ohio
Not listed Columbus Ohio

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02784704, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 5, 2022 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02784704 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →